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Abstract
Background: Diabetes-induced vascular dysfunction may arise from reduced nitric oxide (NO) availability, following
interaction with superoxide to form peroxynitrite. Peroxynitrite can induce formation of 3-nitrotyrosine-modified
proteins. RhoA/ROCK signaling is also involved in diabetes-induced vascular dysfunction. The study aimed to
investigate possible links between Rho/ROCK signaling, hyperglycemia, and peroxynitrite in small coronary arteries.
Methods: Rat small coronary arteries were exposed to normal (NG; 5.5 mM) or high (HG; 23 mM) D-glucose.
Vascular ring constriction to 3 mM 4-aminopyridine and dilation to 1 μM forskolin were measured. Protein
expression (immunohistochemistry and western blot), mRNA expression (real-time PCR), and protein activity
(luminescence-based G-LISA and kinase activity spectroscopy assays) of RhoA, ROCK1, and ROCK2 were determined.
Results: Vascular ring constriction and dilation were smaller in the HG group than in the NG group (P < 0.05);
inhibition of RhoA or ROCK partially reversed the effects of HG. Peroxynitrite impaired vascular ring constriction/
dilation; this was partially reversed by inhibition of RhoA or ROCK. Protein and mRNA expressions of RhoA, ROCK1,
and ROCK2 were higher under HG than NG (P < 0.05). This HG-induced upregulation was attenuated by inhibition
of RhoA or ROCK (P < 0.05). HG increased RhoA, ROCK1, and ROCK2 activity (P < 0.05). Peroxynitrite also enhanced
RhoA, ROCK1, and ROCK2 activity; these actions were partially inhibited by 100 μM urate (peroxynitrite scavenger).
Exogenous peroxynitrite had no effect on the expression of the voltage-dependent K+ channels 1.2 and 1.5.
Conclusions: Peroxynitrite-induced coronary vascular dysfunction may be mediated, at least in part, through
increased expressions and activities of RhoA, ROCK1, and ROCK2.
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Background
Diabetes mellitus (DM) is associated with disturbances
in coronary arterial function that contribute to the detri-
mental effects of DM on the heart. Indeed, DM has been
reported to cause dysfunction of endothelial-dependent
vasodilation of small coronary arteries [1–3], even dur-
ing the early stages of the disease [4]. This impairment
in the relaxation of coronary vessels may involve, at least
in part, reduced availability of nitric oxide (NO) [5, 6].
In turn, this is thought to be due to a decrease in NO
synthase (NOS) activity [7, 8], as well as to the
interaction of NO with superoxide to generate peroxyni-
trite (ONOO−) [9]. Peroxynitrite is a powerful oxidizing
agent that causes nitration of aromatic amino acid resi-
dues, forming 3-nitrotyrosine (3-NT)-modified proteins.
Enhanced 3-NT formation has been reported in an ani-
mal model of DM [10]. Peroxynitrite is known to partici-
pate in DM-induced endothelial dysfunction [11, 12].
Indeed, studies in DM models showed that increases in
peroxynitrite levels were associated with vascular perme-
ability and impaired vasorelaxation [13]. It has also been
shown that peroxynitrite suppresses eNOS expression
through RhoA activation, leading to endothelial dysfunc-
tion [11]. Peroxynitrite leads to the formation of nitro-
tyrosine in the artery walls, which is directly toxic to
endothelial cells and leads to endothelial dysfunction
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[12]. The presence of nitrotyrosine is associated with
microvascular anomalies in DM, and correlate with
blood glucose [14].
RhoA is a small, guanosine-5’-triphosphate binding
protein, bound to the plasma membrane. Upon stimu-
lation, RhoA activates RhoA-associated protein kinase
(ROCK), of which there are two isoforms (ROCK1
and ROCK2) with an overall homology of 65 % [15].
RhoA/ROCK signaling regulates numerous cellular
processes, including gene transcription, organization
of the actin cytoskeleton, and cell contraction, adhe-
sion, motility, proliferation, and differentiation [16].
The RhoA/ROCK signaling pathway has been in-
volved in several pathological conditions [16, 17] in-
cluding hypertension [18, 19], atherosclerosis [20],
stroke [21], coronary vasospasm [22], angina [23],
ischemia-reperfusion injury [24], and heart failure [25,
26]. There is strong evidence that DM increases the
expressions and activities of RhoA and ROCK in vari-
ous tissues, and that the resulting phosphorylation of
downstream targets enhances the contraction of vas-
cular smooth muscle cells [27–33].
Potassium channels regulate K+ efflux and are
major regulators of membrane potential of vascular
smooth muscle cells. Therefore, K+ channel activity is
an important factor involved in the regulation of
vasoconstriction and blood vessel diameter [34].
Voltage-dependent K+ channels (Kv) limit membrane
depolarization to maintain the vascular tone [35].
Kv1.2 and Kv1.5 are subunits that are expressed in
vascular smooth muscle cells [35]. Many vasoconstric-
tors act through the inhibition of K+ channel activity
[35].
However, the precise mechanisms by which peroxyni-
trite impairs the function of small coronary arteries re-
main largely unknown. The aim of the present study was
to explore whether the RhoA/ROCK signaling pathway
and KV are involved in mediating peroxynitrite-induced
impairment of rat small coronary arteries.
Methods
Animals
Male Sprague–Dawley rats (age, 7–8 weeks; weight,
180–220 g) were provided by Vital River Laboratory
Animal Technology Co., Ltd. (Beijing, China). Animals
were housed under specific pathogen-free conditions
and given free access to food and water. All animal ex-
periments were performed in accordance with the
Guidelines for the Care and Use of Laboratory Animals,
Ministry of Science and Technology (Beijing, China).
The study was approved by the Animal Care and Use
Committee of Beijing Friendship Hospital, Capital Med-
ical University (Beijing, China).
Preparation of isolated rat small coronary arteries
Rats were anesthetized with chloral hydrate (0.5 mL/
100 g i.p.) and received heparin (2500 U/kg) to inhibit
blood clot formation. The heart was removed and placed
in HEPES-buffered (Hanks) solution at 4 °C. The cardiac
apex and ascending aorta were fixed using pins, and the
left auricle was identified under a 2 × 10 stereoscopic
microscope (with a halogen lamp as a cold light source;
Nikon, Tokyo, Japan). The left anterior descending
branch of the coronary artery was identified under the
left auricle, and small coronary arteries with diameters
≤200 μm were isolated rapidly as vascular rings of about
2-mm. The endothelium was denuded with air, and de-
nudation was verified by failure to dilate in response to
1 μM acetylcholine.
For the experiments, the isolated vascular rings were
incubated in 6-well dishes at 37 °C for 24 h with Dulbec-
co’s modified Eagle’s medium (DMEM; Gibco, USA)
supplemented with 20 % fetal calf serum (Gibco, USA),
100 U/mL penicillin G, and 100 mg/mL streptomycin.
The vascular rings were divided into the following
groups: normal glucose (NG group, 5.5 mM D-glucose),
L-glucose (LG group, 5.5 mM D-glucose plus
17.5 mM L-glucose), or high glucose (HG group, 23 mM
D-glucose). In experiments of pharmacologic disruption
of the RhoA/ROCK pathway, vascular rings of the HG
group were pre-treated for 16 h with either the RhoA in-
hibitor, C3 transferase (1 μg/ml, HG + C3 group; Cyto-
skeleton, USA), or the ROCK inhibitor, Y-27632 (10 μM,
HG + Y-27632 group; Sigma-Aldrich, St. Louis, MO,
USA), followed by culture in high glucose medium. In
experiments investigating the effects of exogenous per-
oxynitrite, vascular rings of the NG group were incu-
bated (37 °C, 24 h) in the presence of additional agents:
5 μM peroxynitrite (ONOO− group), 5 μM decomposed
peroxynitrite (DC-ONOO− group), or 5 μM peroxyni-
trite plus 100 μM urate (ONOO− + urate group). Peroxy-
nitrite was synthesized according to published methods,
and determined spectrophotometrically using the re-
ported extinction coefficient for peroxynitrite (1670/M/
cm) [36]. Before each application, the stock solution was
diluted in 1 mM NaOH and rapidly added to the cham-
ber to achieve a final concentration of 5 μM. Decom-
posed peroxynitrite was made by leaving peroxynitrite at
room temperature for at least 2 h. Urate (Sigma-Aldrich)
was used as a scavenger of peroxynitrite.
Contraction and relaxation of vascular rings in response
to 4-aminopyridine and forskolin
After incubation with the appropriate experimental solu-
tion, each coronary artery ring was threaded onto two
tungsten filaments (each with a diameter of 40 μm) and
fixed to the bath transducers of a Multi Wire Myograph
System-610 M (DMT, Aarhus, Denmark). The vascular
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ring was bathed in HEPES-buffered solution (8.415 g/l
NaCl, 0.432 g/l KCl, 0.244 g/l MgCl2 · 6H2O, 0.277 g/l
CaCl2, 2 g/l glucose, 1.1915 g/l HEPES) gassed with
100 % O2 and maintained at 37 °C. As a standardization
procedure, the transmural pressure of the vascular ring
was set to a baseline value of 13.33 kPa (100 mmHg);
this was achieved by adjusting the tension of the vascu-




ICi ¼ 205:6þ 2Xi
where:
Pi (kPa) = effective transmural pressure
Ti (mN/mm) = vascular ring tension per unit length
ICi (μm) = vascular ring inner perimeter
Fi (mN) = total tension of the vascular ring, deter-
mined by the myography system
Xi (μm) = distance between the two tungsten wires, de-
termined by the myography system
L (mm) = vascular ring length, determined with a dis-
secting microscope and micrometer
Experiments were performed after an equilibration
period of 60–90 min, during which the bathing medium
was replaced every 15–20 min with pre-heated (37 °C)
HEPES-buffered solution. The tension changes of each
vascular ring were determined automatically by the myo-
graphy system and recorded by a computer running the
Chart 5.5 software (ADInstruments, Dunedin, New Zea-
land). Before examining the responses of the vascular
rings to vasoactive substances, the rings were exposed
repeatedly to 120 mM KCl until the contraction ampli-
tude differences for three successive applications of KCl
were less than 10 %; tension was then allowed to
stabilize for 30 min before vasoactive substances were
administered. Contraction was measured in response to
a range of concentrations (0.1–3 mM) of 4-
aminopyridine (4-AP, Sigma-Aldrich), a blocker of the
Kv1 K
+ channels. Relaxation in response to 1 μM forsko-
lin (an adenylyl cyclase activator; Sigma-Aldrich) was
also assessed.
Isolation of vascular smooth muscle cells from rat small
coronary arteries
Small coronary arteries with diameters ≤200 μm were
obtained as described above. Coronary vascular smooth
muscle cells (VSMCs) were isolated enzymatically. The
adventitia was dissected from the small coronary arter-
ies, and the vessel washed three times with sterile Hanks’
buffered salt solution. The vessel was incubated for
10 min at room temperature with 1 mL of phosphate-
buffered saline (PBS) containing 0.1 % bovine serum al-
bumin (BSA), and subsequently digested for 10 min at
37 °C in 1 mL of PBS containing 0.15 % papain, 0.1 %
dithioerythritol (DTE), and 0.1 % BSA. The vessel was
then incubated for 10 min at 37 °C with 1 mL of PBS
containing 0.2 % collagenase, 0.05 % elastase, and 0.1 %
soybean trypsin inhibitor. Subsequently, 5 mL of DMEM
containing 20 % fetal bovine serum (FBS) were added to
stop digestion. The mixture was centrifuged at 1000 rpm
for 7 min, and the supernatant was discarded. The pellet
was washed with sterile PBS and resuspended in 4–5 mL
of culture medium. The resuspended cells were seeded
into culture flasks and cultured for 24 h (DMEM con-
taining 20 % FBS). When the cells were fully adherent,
as determined under an inverted microscope, the culture
medium was changed to DMEM containing 10 % FBS,
100 U/mL of penicillin G, and 100 μg/mL of strepto-
mycin. Primary VSMCs were cultured for 7 days to
reach a logarithmic phase. The cell passages were per-
formed when cell coverage reached 80 %. Culture
medium was discarded, and the cells were washed with
sterile PBS and digested with 1 mL of 0.25 % trypsin (2–
3 min, 37 °C). Digestion was terminated with culture
medium containing FBS when the morphology of 80–
90 % of the cells changed from spindle-shaped to round.
The digested cells were seeded into flasks for culture,
and passages could be performed after 3–4 days. Cells
were then used for glucose exposure experiments.
Smooth muscle cells were identified by immunofluor-
escence. Single-cell suspensions were seeded into dishes
containing coverslips, and a coverslip covered with a
monolayer of cells was fixed with 95 % pre-cooled etha-
nol for 30 min. After three washes with PBS, the cells
were incubated with the primary antibody (mouse anti-
rat alpha-smooth muscle actin polyclonal antibody;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
30 min at 37 °C. After three washes with PBS, the cells
were incubated with the secondary antibody (IgG-FITC-
labeled chicken anti-mouse secondary antibody; Santa
Cruz Biotechnology) for 30 min at 37 °C. After washing
with PBS (three times), 4′,6-diamidino-2-phenylindole
(DAPI) was added for 2 min (to stain the nuclei). After
three washes with PBS, the coverslip was mounted onto
a slide with mounting medium, and the cells were ob-
served using a fluorescence microscope (Nikon, Tokyo,
Japan).
Real-time PCR for mRNA expression
Total RNA of cultured coronary vascular smooth muscle
cells was extracted with Trizol (Invitrogen, Carlsbad,
CA, USA), and RNA concentration and purity were de-
termined using an ultraviolet spectrophotometer. Total
RNA (1 μg) was reverse-transcribed into cDNA with re-
verse transcriptase (Shanghai Jierdun Biotech Co. Ltd.,
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Shanghai, China), according to the manufacturer’s proto-
col. The expressions of RhoA, ROCK1, ROCK2, Kv1.2,
and Kv1.5 mRNA were assessed by real-time polymerase
chain reaction (PCR) of the cDNA (2 μg), using an ABI
Step One Plus Real-Time-PCR System (Applied Biosys-
tems, Foster City, CA, USA), SYBR Green Master Mix












F: 5′CGT CAG CTT CTG TCT GGA AAC C 3′






R: 5′- GTAGCCCAGGATGCCC - 3′
GAPDH was used as a reference to obtain the relative
fold changes for the target genes, using the comparative
Ct method. Relative mRNA expressions were estimated
using the 2-△△CT method.
Immunohistochemistry
Standard immunohistochemistry protocols were applied
to small coronary arteries treated for 24 h with the vari-
ous experimental solutions, in order to determine the
protein expression levels of RhoA, ROCK1, and ROCK2.
The small coronary arteries were fixed with 4 % parafor-
maldehyde and sectioned (4 μm). The following primary
antibodies (100 μL) were used: anti-RhoA (1:200 dilu-
tion; BS1782; Bioworld Technology Inc., St. Louis Park,
MN, USA), anti-ROCK1 (1:200 dilution; sc-6055; Santa
Cruz Biotechnology), and anti-ROCK2 (1:250 dilution;
sc-1851; Santa Cruz Biotechnology). The secondary anti-
body was biotinylated goat anti-rabbit IgG (Beyotime In-
stitute of Biotechnology, Shanghai, China). Sections were
visualized with diaminobenzidine (DAB; Shanghai Jier-
dun Biotech) and counterstained with hematoxylin and
eosin (H&E). Images were captured with a digital camera
(Nikon) and analyzed using the IMS imaging processing
system (Shanghai Jierdun Biotech). Positively stained re-
gions were counted and analyzed. Cardiomyocytes were
excluded.
Immunoprecipitation
Adherent cells were cultured in 10-cm dishes for protein
isolation. The cell culture medium was discarded. The
cells were washed with PBS, and 1 mL of lysis buffer
was added for cell lysis. A 200–1000 μL sample contain-
ing about 200–1000 μg of protein was mixed with 1 μg
of IgG (that shared the same host species as the IgG
used in the immunoprecipitation) and 20 μL of protein
A/G agarose. The mixture was incubated at 4 °C for 30–
120 min, with gentle agitation, and then centrifuged at
1000 g for 5 min. The supernatant was isolated for sub-
sequent protein immunoprecipitation. Primary anti-
bodies (0.2–2 μg) against RhoA (1:400), ROCK1 (1:400),
ROCK2 (1:400), Kv1.2 (1:500), or Kv1.5 (1:500) were
added to the supernatant, and the mixture was incu-
bated overnight at 4 °C with gentle agitation. Then,
20 μL of thoroughly resuspended protein A/G agarose
was added, and this was incubated for a further 1–3 h at
4 °C, with gentle agitation. The mixture was centrifuged
at 1000 g for 5 min or transiently at high speed, and the
supernatant was discarded. The pellet was washed five times
with 0.5–1 mL of lysis buffer (used for protein isolation) or
PBS, and resuspended in 20–40 μL of 1× SDS-PAGE load-
ing buffer. After transient centrifugation at high speed, the
sample was boiled at 100 °C for 3–5 min. Partial or total
samples were used for protein quantification or SDS-PAGE
electrophoresis, or stored at −20 °C for later use.
Western blotting for protein expression
Total protein was extracted from artery rings, and the
protein concentration determined using a bicinchoninic
acid (BCA) protein assay kit (Thermo Fisher Scientific,
Waltham, MA, USA). Immunoblotting was performed
with the following primary antibodies: anti-RhoA (Bio-
world), anti-ROCK1 (Santa Cruz Biotechnology), anti-
ROCK2 (Santa Cruz Biotechnology), anti- Kv1.2, or anti-
Kv1.5. HRP-conjugated anti-rabbit secondary antibody
was used at a dilution of 1:2000. Detection of GAPDH (di-
luted 1:1500; #5471; Cell Signaling Technology, Danvers,
MA, USA) served as an internal loading control. All blots
were scanned with the LabWorks image processing sys-
tem (UVP Inc., Upland, CA, USA). Protein band pixel
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values were calculated using Gel-pro Analyzer 4.0 (Media
Cybernetics Inc., Rockville, MD, USA).
Measurement of RhoA and ROCK activities
RhoA activation was measured using the luminescence-
based G-LISA Activation Assay kit (Cytoskeleton Inc.,
Denver, CO, USA), according to the manufacturer’s in-
structions. Values were normalized to the protein con-
tent using a colorimetric assay (Bio-Rad Laboratories,
Hercules, CA, USA), according to the manufacturer’s
recommendations. ROCK1 and ROCK2 activities were
detected using the Kinase Activity Spectroscopy Kit
(GMS50184.3 for ROCK1 and GMS50184.1 for ROCK2;
Genmed Scientific Inc., Arlington, MA, USA), according
to the manufacturer’s instructions.
Statistical analysis
Continuous data were expressed as means ± standard de-
viation (SD). Statistical analyses were performed using
SPSS 18.0 (IBM, Armonk, NY, USA). Comparisons be-
tween groups were performed using one-way analysis of
variance (ANOVA) or the Student’s t-test, as appropri-
ate. The Bonferroni correction was applied when com-
paring three or more groups. P values <0.05 were
considered statistically significant.
Results
Impairment of vascular ring contraction and dilation by
high glucose or peroxynitrite may involve RhoA/ROCK
signaling
Figure 1a presents concentration-response curves show-
ing the contractile responses of vascular rings in the
various experimental groups treated with 4-AP. Maximal
contraction in response to 3 mM 4-AP, was significantly
smaller in the LG (2.08 ± 0.17 mN) and HG (1.37 ± 0.22
mN) groups than in the NG group (3.15 ± 0.31 mN) (P
< 0.05; n = 6). Interestingly, inhibition of RhoA or ROCK
partially reversed this effect of high glucose: the maximal
contractile response of rings treated with 4-AP was sig-
nificantly larger in the HG + C3 (2.13 ± 0.09 mN) and
HG + Y-27632 (2.02 ± 0.16 mN) groups than in the HG
group (P < 0.05; n = 6). Similar observations were made
in experiments using forskolin (Fig. 1b): dilation in re-
sponse to 1 μM forskolin was significantly reduced in
the LG (39.47 ± 1.32 %) and HG (35.20 ± 1.98 %) groups
compared with the NG group (48.97 ± 1.77 %), and was
higher in both the HG + C3 (39.80 ± 1.59 %) and HG +
Y-27632 (39.68 ± 1.57 %) groups than in the HG group
(P < 0.05; n = 6).
Additional experiments were carried out to determine
whether exogenous peroxynitrite (5 μM) could mimic
these effects of high glucose. The contractile response of
rings treated with 3 mM 4-AP was significantly reduced
in the ONOO− group (1.54 ± 0.21 mN) compared with
the NG group (3.15 ± 0.31 mN) (P < 0.05; n = 6), but
DC-ONOO− was without effect (2.95 ± 0.26 mN). Fur-
thermore, the attenuation of contraction by ONOO- was
inhibited (albeit not completely) by urate (2.39 ± 0.18
mN), C3 transferase (2.17 ± 0.15 mN), and Y-27632
(2.27 ± 0.10 mN) (P < 0.05 compared with the ONOO−
group; n = 6) (Fig. 1c). Similarly, relaxation to forskolin
was significantly smaller in the ONOO− group (36.37 ±
1.80 %) than in the NG (48.97 ± 1.77 %), DC-ONOO−
(48.55 ± 1.64 %), ONOO− + urate (44.17 ± 1.14 %),
ONOO− + C3 (42.02 ± 1.73 %), and ONOO− + Y-27632
(41.22 ± 1.53 %) groups (P < 0.05; n = 6) (Fig. 1d).
Treatment with high glucose increases protein
expressions of RhoA, ROCK1, and ROCK2 detected by
immunohistochemistry in denuded vessels
Figure 2 shows representative images obtained from im-
munohistochemistry experiments carried out to detect
the protein expressions of RhoA, ROCK1, and ROCK2
in the various groups. Quantitative analyses of the im-
munohistochemistry data are shown in Fig. 3. Protein
expressions of RhoA, ROCK1, and ROCK2 were signifi-
cantly higher in the HG group than in the NG group (P
< 0.05; n = 3). Importantly, inhibition of RhoA (C3 trans-
ferase) or ROCK (Y-27632) significantly attenuated the
upregulation of ROCK1 and ROCK2 induced by high
glucose, while Y-27632 inhibited the upregulation of
RhoA (P < 0.05; n = 3). This suggests that an increase in
RhoA/ROCK signaling induced by high glucose can in
turn feedback to upregulate the protein expressions of
RhoA, ROCK1, and ROCK2.
Treatment with high glucose increases mRNA and protein
expressions of RhoA, ROCK1, and ROCK2 detected by
real-time PCR and Western blotting
The mRNA expression of RhoA, ROCK1, and ROCK2,
detected using real-time PCR, was significantly enhanced
by high glucose (P < 0.05; n = 5; Fig. 4a–c). No significant
effects of exogenous peroxynitrite were observed (Fig. 4d–
f ), although a trend toward a small increase in expression
could not be excluded. Consistent with the immunohisto-
chemistry data, high glucose significantly enhanced the
protein expressions of RhoA, ROCK1, and ROCK2 mea-
sured using western blotting (P < 0.05; n = 5; Fig. 5).
Treatment with high glucose or exogenous peroxynitrite
increases the activity of RhoA, ROCK1, and ROCK2
Further studies were undertaken to determine whether
the high glucose-induced upregulation of RhoA, ROCK1,
and ROCK2 expression translated into enhanced activities.
As shown in Fig. 6a–c, treatment with high glucose was
associated with significant increases in RhoA, ROCK1,
and ROCK2 activity (P < 0.05; n = 5). Interestingly, 5 μM
peroxynitrite (but not decomposed peroxynitrite)
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mimicked the effects of high glucose, and these actions of
exogenous peroxynitrite were partially inhibited by urate
(Fig. 6d–f ).
mRNA and protein expressions of Kv1.2 and Kv1.5 are not
affected by exogenous peroxynitrite
To investigate whether the functional impairment of
vascular ring contraction/relaxation by high glucose
might involve peroxynitrite-mediated changes in the ex-
pressions of Kv, the mRNA and protein expression of
Kv1.2 and Kv1.5 were determined. As shown in Fig. 7,
exogenous peroxynitrite (5 μM) had no significant
effects on the mRNA and protein expression of Kv1.2
and Kv1.5 (n = 5).
Exogenous peroxynitrite induces 3-NT-modification of
proteins
Exogenous peroxynitrite (5 μM) caused significant in-
creases in the levels of 3-NT-modified RhoA, ROCK1,
ROCK2, and Kv1.2 (P < 0.05; n = 5; Fig. 8). However, no
effect on Kv1.5 was observed (Fig. 8).
Discussion
The aim of the present study was to explore whether the
RhoA/ROCK signaling pathway is involved in mediating
Fig. 1 Impairment of vascular ring contraction and dilation by high glucose involves RhoA/ROCK signaling. a Concentration-response curves
showing the contractile responses of rat small coronary artery vascular rings treated with 4-AP (a voltage-gated K+ channel blocker; 0.1–3 mM)
under various experimental conditions. Treatment with high glucose (23 mM D-glucose) was associated with attenuation of contraction of rings
treated with 4-AP (compared with 5.5 mM D-glucose) that was partially reversed by C3 transferase (a RhoA inhibitor) and Y-27632 (a ROCK
inhibitor). b Rat small coronary artery vascular rings treated with high glucose (23 mM D-glucose) showed an impairment of dilation (compared
with 5.5 mM D-glucose) in response to 1 μM forskolin (adenylyl cyclase activator); this impairment was partially reversed by C3 transferase and
Y-27632. Data are shown as mean ± SD (n = 6). *P < 0.05 vs. NG. #P < 0.05 vs. HG. c Concentration-response curves showing the contractile responses
of rat small coronary artery vascular rings to 4-AP (a voltage-gated K+ channel blocker; 0.1-3 mM) under various experimental conditions. Treatment
with peroxynitrite (5 μM peroxynitrite) was associated with attenuation of contraction of rings treated with 4-AP (compared with 5.5 mM D-glucose
and 5 μM decomposed peroxynitrite) that was partially reversed by urate, C3 transferase, and Y-27632. d Rat coronary small coronary artery rings
treated with ONOO (5 μM peroxynitrite) showed an impairment of dilation (compared with 5.5 mM D-glucose and 5 μM decomposed peroxynitrite) in
response to 1 μM forskolin (adenylyl cyclase activator); this impairment was partially reversed by urate, C3 transferase, and Y-27632. Data are shown as
mean ± SD (n = 6). *P < 0.05 vs. ONOO
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peroxynitrite-induced impairment of rat small coronary
arteries. The main findings were that short-term exposure
to high glucose and peroxynitrite caused functional im-
pairment of rat small coronary artery rings that was par-
tially reversed by RhoA or ROCK inhibition, and
enhancement of RhoA, ROCK1, and ROCK2 activity.
Therefore, increased RhoA, ROCK1, and ROCK2 expres-
sion and/or activities may contribute to peroxynitrite-
induced coronary vascular dysfunction. Although the
underlying mechanisms remain to be established, the ef-
fects of peroxynitrite may involve 3-NT modification of
RhoA, ROCK1, ROCK2, and/or other proteins, which in
turn enhances RhoA/ROCK signaling. Vascular ring in-
crease in constrictor tone to 4-AP treatment was smaller
in HG and peroxynitrite-treated vessels, meaning that Kv
channels contribute less to the maintenance of dilator
tone in HG or peroxynitrite incubated vessels than in NG
vessels.
The interaction of NO with superoxide reduces NO
availability (which contributes to coronary vascular dys-
function) and generates peroxynitrite that causes nitra-
tion of various proteins [5, 6, 9]. Increased 3-NT
formation has been observed in an animal model of DM
[10], and peroxynitrite has been suggested to target sub-
cellular compartments in vascular endothelium [37].
Interestingly, the enzymes involved in NO synthesis are
compartmentalized in caveolae [38], and the impairment
of flow-mediated dilation of small coronary arteries in
patients with DM may be due to disruption of caveolae
by peroxynitrite and hence endothelial NOS uncoupling
[39]. Our observations that peroxynitrite mimicked the
effects of high glucose (in terms of coronary arteriolar
dysfunction) suggest that nitration of cellular proteins
contributes to the detrimental effects of DM on the
coronary circulation, but these findings must be taken
with caution because there was no endothelial contribu-
tion in the present study.
RhoA/ROCK signaling is involved in numerous cellular
processes, and may play a role in several pathological con-
ditions [16, 17]. Various studies have reported that DM in-
creases the expression and activity of RhoA and ROCK
[27–33], consistent with the effects of HG observed in the
present study. Both ROCK1 and ROCK2 are expressed in
vascular endothelial and smooth muscle cells [33, 40]. In
models of DM, ROCK inhibition improves microvascular
damage, enhances cerebral vasodilation, reverses vasocon-
striction, and improves coronary dysfunction through an
enhancement of endothelial NOS [26, 27, 32, 33, 41, 42].
An impairment of endothelial NOS by RhoA and ROCK
inhibitors would mitigate against peroxynitrite-induced
disruption of caveolae and endothelial NOS uncoupling
[39], potentially underlying our observations that C3
transferase and Y-27632 attenuated peroxynitrite-induced
vascular dysfunction. But again, the effect of endothelium
could not be assessed in the present study, and additional
observations are necessary.
The findings that impaired vascular function and in-
creased RhoA, ROCK1, and ROCK2 expression/activity
occurred after only a 24-h exposure to HG imply that acti-
vation of the RhoA/ROCK pathway is an early event in
the pathogenesis of diabetic complications. Endothelial-
dependent vasodilation is compromised during the early
stages of DM [11, 43]. Interestingly, in a rat model of
early-stage DM, there was a trend toward upregulation of
ROCK1 and ROCK2 expression, and a larger effect of
ROCK inhibition (with fasudil) in the presence of NOS
and cyclooxygenase blockade; furthermore, fasudil inhib-
ited the occurrence of focal and segmental constrictions
Fig. 2 Immunohistochemistry showing protein expressions of RhoA, ROCK1, and ROCK2 in rat coronary small coronary artery rings. Sections were stained
with rabbit primary antibodies against RhoA, ROCK1, or ROCK2, followed by goat anti-rabbit biotinylated secondary antibody, and then visualized with
diaminobenzidine. Sections were counterstained with hematoxylin and eosin. Brown staining in the image is indicative of expression of the protein of interest.
Treatment with high glucose (23 mM D-glucose) was associated with enhanced expressions of RhoA, ROCK1, and ROCK2 compared with normal glucose
(5.5 mM). These effects of high glucose were partially reversed by C3 transferase (a RhoA inhibitor) and Y-27632 (a ROCK inhibitor). NG: 5.5 mM glucose; HG:
23 mM D-glucose; HG+C3: 23 mM D-glucose and 1 μg/ml C3 transferase; HG+ Y27632: 23 mM D-glucose and 10 μM Y-27632. Magnification: ×200
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[44]. The involvement of RhoA/ROCK signaling in the
early stages of DM would make ROCK a promising thera-
peutic target for treating diabetic complications [16, 45].
Hyperglycemia has been suggested to stimulate RhoA/
ROCK signaling through the generation of reactive oxy-
gen species (ROS) [46]. Interestingly, peroxynitrite may
be a mediator of enhanced ROCK signaling in endothe-
lial cells [40, 47], in agreement with the present findings.
Although the mechanisms remain unclear, peroxynitrite
and the Rho/ROCK pathway may interact via a positive
feedback loop, as has been proposed for the relationship
between Rho/ROCK, protein kinase C-β2 (PKCβ2), indu-
cible NOS (iNOS), and ROS. PKCβ2 [48] is believed to
contribute to diabetic complications, and inhibitors of
this kinase can improve DM-induced retinopathy, car-
diomyopathy, nephropathy, and neuropathy [49, 50].
Hyperglycemia is thought to activate PKCβ2, which
in turn activates iNOS and RhoA/ROCK signaling
[51–53]. PKCβ2 inhibition reduces iNOS-mediated
cardiovascular abnormalities in diabetic rats [52].
iNOS may contribute to enhanced RhoA and ROCK
expressions/activities; consistent with our observa-
tions, ROCK inhibition can downregulate RhoA ex-
pression [53]. Rats with experimental DM show
increases in cardiac ROCK2 expression and PKCβ2
expression and activity; intriguingly, ROCK2 appears
to directly interact with and activate PKCβ2 through
phosphorylation at the T641 site [51]. Thus, RhoA/
ROCK may contribute to cardiac dysfunction in DM
by activating PKCβ2 and generating ROS, through a
positive-feedback loop involving iNOS [54]. ROS may
contribute to the PKCβ2 activation [55] and iNOS upregu-
lation [56], while the effects of PKCβ2 may, in part, be me-
diated by ROS [57, 58] and induction of iNOS [52].
Further research is required to establish whether
peroxynitrite-induced activation of the RhoA/ROCK path-
way leads to alterations in NO signaling (such as iNOS in-
duction) that exacerbate the generation of peroxynitrite.
Fig. 3 Mean protein expressions of RhoA, ROCK1, and ROCK2 in rat small coronary artery vascular rings determined from immunohistochemistry
experiments. a Protein expression of RhoA. b Protein expression of ROCK1. c Protein expression of ROCK2. NG: 5.5 mM glucose; LG: 5.5 mM
D-glucose plus 17.5 mM L-glucose; HG: 23 mM D-glucose; HG + C3: 23 mM D-glucose and 1 μg/ml C3 transferase; HG + Y27632: 23 mM
D-glucose and 10 μM Y-27632. Data are shown as mean ± SD (n = 6 rats, 5–6 vessels from each). * P < 0.05 compared with the NG group;
# P < 0.05 compared with the LG group; ▲ P < 0.05 compared with the HG group. Cardiomyocytes were excluded
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In addition, other signaling mechanisms may be involved
in alterations to NO signaling, such as the JNK and
TGFβ/SMAD pathways [59].
KV are involved in the regulation of vascular tone by
limit membrane depolarization [35]. A recent study has
shown that diabetes led to reduced presence of KV1.2 in
nerves from diabetic mice and diabetic patients [60]. An-
other study suggests that diabetes might be associated
with gender-specific decreases in KV1.5 levels in myo-
cytes from male mice, and that this effect might be
triggered by the renin-angiotensin system [61]. In the
present study, exogenous peroxynitrite had no signifi-
cant effects on the mRNA and protein expression of
Kv1.2 and Kv1.5, but significantly increased the levels of
3-NT-modified Kv1.2. A previous study revealed that ex-
cess peroxynitrite production might impair KV function
in DM, which is consistent with the present study [62].
Another study has shown that peroxynitrite over-
production induced by high glucose impaired KV-medi-
ated vascular dilation mediated by cAMP [63]. 4-AP is a
Fig. 5 Protein expressions of RhoA, ROCK1 and ROCK2 in rat coronary vascular smooth muscle cells. Protein expression was determined using the
Western blot technique. a Representative blots for RhoA, ROCK1, and ROCK2; GAPDH expression was used as an internal reference. b Mean data
for protein expression levels. Treatment with peroxynitrite was associated with enhanced the expression of RhoA, ROCK1, and ROCK2 compared
with controls. NG: 5.5 mM glucose; LG: 5.5 mM D-glucose plus 17.5 mM L-glucose; HG: 23 mM D-glucose. Data are shown as mean ± SD (n = 5).
* P < 0.05 compared with the NG group
Fig. 4 mRNA expressions of RhoA, ROCK1, and ROCK2 in rat coronary vascular smooth muscle cells. mRNA expression was determined using
real-time PCR. Treatment with high glucose (23 mM D-glucose) resulted in an increase in the mRNA expression of RhoA (a), ROCK1 (b), and
ROCK2 (c). However, exogenous peroxynitrite was without significant effect on the mRNA expression of RhoA (d), ROCK1 (e), and ROCK2 (f). NG:
5.5 mM glucose; LG: 5.5 mM D-glucose plus 17.5 mM L-glucose; HG: 23 mM D-glucose; ONOO: 5 μM peroxynitrite; DC-ONOO: 5 μM decomposed
peroxynitrite; ONOO + Urate: 5 μM peroxynitrite and 100 μM urate (to scavenge peroxynitrite). Data are shown as mean ± SD (n = 5). * P < 0.05
compared with the NG group
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Fig. 7 mRNA and protein expression of Kv1.2 and Kv1.5 in coronary vascular smooth muscle cells. a Kv1.2 mRNA expression (real-time PCR) was not affected by
5 μM peroxynitrite. b Kv1.5 mRNA expression (real-time PCR) was not influenced by 5 μM peroxynitrite. c Representative blots for Kv1.2 and Kv1.5. GAPDH
expression was used as an internal reference. d Mean data for protein expression levels. Peroxynitrite (5 μM) had no effect on the protein expression of Kv1.2
and Kv1.5. NG: 5.5 mM glucose; ONOO
−: 5 μM peroxynitrite; DC-ONOO: 5 μM decomposed peroxynitrite; C3 or ONOO−+C3: 5 μM peroxynitrite and C3
transferase (to inhibit RhoA); Y-27632 or ONOO−+Y-27632: 5 μM peroxynitrite and Y-27632 (to inhibit ROCK). Data are shown as mean± SD (n=5)
Fig. 6 RhoA, ROCK1, and ROCK2 activities in rat coronary vascular smooth muscle cells. RhoA activation was measured using the luminescence-
based G-LISA Activation Assay kit; ROCK1 and ROCK2 activities were detected using the Genmed Kinase Activity Spectroscopy Kit. Treatment with
high glucose (23 mM D-glucose) resulted in an increase in the activities of RhoA (a), ROCK1 (b), and ROCK2 (c). Similarly, treatment with 5 μM
peroxynitrite was associated with increases in RhoA (a), ROCK1 (b), and ROCK2 (c) activities; these effects could be partially inhibited by 100 μM
urate (a scavenger of peroxynitrite). NG: 5.5 mM glucose; LG: 5.5 mM D-glucose plus 17.5 mM L-glucose; HG: 23 mM D-glucose; ONOO−: 5 μM
peroxynitrite; DC-ONOO: 5 μM decomposed peroxynitrite; ONOO + Urate: 5 μM peroxynitrite and 100 μM urate (to scavenge peroxynitrite). Data
are shown as mean ± SD (n = 5). * P < 0.05 compared with the NG group; & P < 0.05 compared with the ONOO− group
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KV blocker that allow the separation of the effects of KV
and Ca2+-activated K+ channels [35]. In the present
study, 4-AP decreased the contraction response to a
greater extent in glucose-treated rings compared with
controls. Forskolin is an activator of adenylyl cyclase,
leading to an increase in intracellular cAMP levels. The
decreased vasorelaxation observed in the present study
also point toward a role of KV in the process of impaired
vascular response in DM. Taken together, these results
suggest that Kv channels contribute less to the mainten-
ance of dilator tone in HG or peroxynitrite incubated
vessels than in NG vessels. However, further study is ne-
cessary to adequately assess the role and exact mecha-
nisms of KV in DM and vascular dysfunction.
Conclusions
Vascular ring increase in constrictor tone to 4-AP treat-
ment was smaller in HG and peroxynitrite-treated vessels,
meaning that Kv channels contribute less to the mainten-
ance of dilator tone in HG or peroxynitrite incubated ves-
sels than in NG vessels, possibly via 3-NT modification of
RhoA, ROCK1, ROCK2, KV1.2, and/or other proteins. Im-
portantly, these results suggest that even a short-term
exposure to glucose was might be sufficient to induce this
impaired response.
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